Guidant to restart shipment of AtheroCath:
This article was originally published in Clinica
Guidant subsidiary Devices for Vascular Intervention (DVI) has received US FDA approval of a PMA supplement for its AtheroCath-GTO atherectomy catheter, allowing it to resume production and shipment of the device. DVI stopped shipment of the AtheroCath last month pending review by the FDA of modifications to the catheter and the device has not been sold in the US for some 30 days.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.